SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert DeHaven who wrote (426)6/3/1998 6:53:00 PM
From: Manny Gugliuzza   of 1510
 
ALL**************************************

what i find most encouraging of all the recent new stages of development for H I V therapies is that REMUNE has or been chosen to qualify itself with and against the most effective therapy allowed buy the FDA to date, the triple combo drugs.

and where are most of these other companies in their phaseIII? just entering the tunnel?! where are we comparatively? near the end!!

did you know the FD@#*@'*# A held up the approval of human LYME vaccine after the successful completion of phaseIII due to lack of follow up booster vaccine studies.

REMUNE as a therapy will receive earlier approval in combination studies with the triple drugs possibly after this PHASE II in september. a phase III is not need with these triple drugs!!!

REMUNE alone will be completed in MARCH for PHASE III and hopefully achieve vaccine status soon after.

this sharp up swing ongoing now shows a lot of support from the 11$ high points of the previous reverse head and shoulder we came out of.

checking the weekly chart again smooths out all these rough edges and the support areas are more evident.

could get a sharp snap up just like we came down if support continues above 50 day MA. very bullish here.

ar
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext